Camber Pharmaceuticals Announces Addition of Erlotinib Tablets

Camber Pharmaceuticals is excited to announce the addition of Erlotinib Tablets.

Erlotinib Tablets are a kinase inhibitor indicated for:

• The treatment of patients with metastatic non-small cell lung cancer (NSCLC)
• First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.

Erlotinib Tablets are available in 25 mg, 100 mg, and 150 mg strengths, packaged in 30-count bottles.

To find out more information on Erlotinib Tablets please visit: www.camberpharma.com/erlotinib